Incretin-based therapy

DRUG3 trials

Sponsors

Nagaoka Red Cross Hospital, The Cleveland Clinic, Biruni University

Conditions

Liver FibrosisMetabolic Dysfunction-Associated Steatohepatitis (MASH)Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)Non-Alcoholic Fatty Liver DiseaseObesityObesity (BMI>30)Type 2 Diabetes Mellitus

Phase 4

Fibrosis Lessens After Metabolic Surgery

RecruitingNCT06374875

The Cleveland ClinicLiver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) +2

Start: 2024-07-11End: 2029-12-31Target: 120Updated: 2026-07-31

Unknown Phase

A Cohort Study of Incretin-based Therapy Combined With Insulin in Type 2 Diabetic Patients for 5 Years

Nagaoka Red Cross HospitalType 2 Diabetes Mellitus

Start: 2012-10-31End: 2018-10-31Target: 500Updated: 2012-09-11

Machine Learning Prediction of Respiratory Muscle Changes and Ventilatory Responses After Incretin-Based Therapy in Obesity

Not yet recruitingNCT07663591

Biruni UniversityObesity (BMI>30)

Start: 2026-07-01End: 2026-07-30Target: 48Updated: 2026-06-23